RxDoctor Payments Data

Sudhir Jain, MD

Cardiovascular Disease · Saint Louis, MONPI 1487698809

Payments from drug & device makers

$526in general payments, 2019–2025

Across 9 payments — averaging $58.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$297
  • Biotronik Inc.$126
  • Sanofi-aventis U.S. LLC$22
  • Hologic Sales And Service, LLC$22
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$19
  • AstraZeneca$15
  • plus $25 from 2 others

What the payments were for

  • Food & beverage$51498%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$526 in reported general payments places this provider in the 25th percentile of 391 cardiovascular disease providers in Missouri.

See all cardiovascular disease providers in Missouri

Medicare billing

Part B allowed, 2024
$744,372
Medicare patients
1,183
Services billed
9,722

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban985$1,071,046
EntrestoSacubitril/Valsartan527$587,726
Repatha SureclickEvolocumab381$347,183
FarxigaDapagliflozin Propanediol330$306,899
MultaqDronedarone Hcl98$157,730
XareltoRivaroxaban121$125,986
JardianceEmpagliflozin71$74,680
Praluent PenAlirocumab77$58,732
BrilintaTicagrelor58$35,500
Ranolazine ErRanolazine293$22,015
Repatha SyringeEvolocumab12$17,859
Metoprolol Succinate1,421$16,764
Atorvastatin Calcium1,779$15,342
Carvedilol1,224$9,380
Isosorbide Mononitrate ErIsosorbide Mononitrate534$7,909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$15$342,400388 claims
Sanofi-aventis U.S. LLCMultaq$22$157,73098 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 391 cardiovascular disease providers in Missouri.

Other cardiovascular disease in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →